Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shouval Roni, Strouse Christopher, Kim Soyoung, Oloyede Temitope, Ahmed Sairah, Awan Farrukh T, Luan Danny, Bachanova Veronika, Badar Talha, Bar Merav, Barba Pere, Beitinjaneh Amer M, Cashen Amanda, Dholaria Bhagirathbhai, Elsawy Mahmoud, Ganguly Siddhartha, Geethakumari Praveen Ramakrishnan, Greenbaum Uri, Hashmi Hamza, Hill LaQuisa C, Jain Michael D, Jain Tania, Kebriaei Partow, Kittai Adam S, Locke Frederick L, Lulla Premal D, Mead Elena, McGuirk Joseph P, Mussetti Alberto, Nishihori Taiga, Olson Amanda L, Pennisi Martina, Perales Miguel-Angel, Riedell Peter A, Saber Wael, Mirza Abu-Sayeef, Magalhaes-Silverman Margarida, Shpall Elizabeth J, Sorror Mohamed, Wudhikarn Kitsada, Turtle Cameron J, Moskop Amy, Pasquini Marcelo C
Аннотация
Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for relapsed-refractory large B-cell lymphoma (LBCL). However, toxicities, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), remain significant concerns. Analyze temporal trends, risk factors, and associations between these toxicities and their severity. In this registry study by the Center for International Blood and Marrow Transplant Research, we studied CRS and ICANS in 1916 LBCL patients treated with commercial CAR-T therapies (axicabtagene ciloleucel 74.9%, tisagenlecleucel 25.1%) between 2018 and 2020. Outcomes include development of CRS/ICANS, timing and severity according to ASTC grading, overall survival (OS). Risk factors were assessed using Cox proportional hazards model. Among patients developing CRS (75.2%), 11.3% had grade ≥3 CRS. Among patients developing ICANS (43.5%), 47.7% had grade ≥3 ICANS. Among patients developing CRS, severe CRS rates decreased from 14.0% in 2018 to 9.2% in 2020 (P< .01). However, the proportion of severe ICANS in patients who developed ICANS remained statistically unchanged (41.5% in 2018 to 53.7% in 2020, P= .10). CRS and ICANS were correlated: 57.1% of patients with CRS also experienced ICANS, and CRS was reported in 97.5% of ICANS cases, suggesting a potential continuum between toxicities. Axicabtagene ciloleucel was associated with higher risk of any grade CRS (OR, 4.6; 95% CI, 3.65 to 5.81) and ICANS (OR, 5.85; 95% CI, 4.48 to 7.64) as well as early and severe forms of both complications. Older age, lower performance status, and elevated lactate dehydrogenase levels prior to infusion also variably predicted these toxicities. In a landmark analysis starting 30 days postinfusion, patients with severe CRS or severe ICANS had shorter OS compared to those without these toxicities. High grades of CRS improved over time likely related to earlier intervention, development of ICANS is intrinsically related with CRS. These findings underscore the need for effective strategies to mitigate these toxicities and improve CAR-T safety.